Pharmaceutical Technology's In the Lab eNewsletter
Comecar will provide cell culture equipment for biopharmaceutical company CO.DON AG's new production site in Leipzig, Germany.
Comecer Group, an Italian provider of isolation equipment and systems for the pharmaceutical and nuclear medicines industries, announced on Jan. 18, 2018 that it signed an agreement with CO.DON AG, a German biopharmaceutical company focused on autologous cell therapies, to supply modular isolator and cell culture incubation systems in aseptic environment for CO.DON AG's new production site being built in Leipzig, Germany. The contract is valued at approximately EUR 10 million (US$12 million). Installation and startup of the equipment is expected in the next 10-12 months.
"We are honored to be part of this great project in what is considered the future of medicine. The fact that our patented technology has been selected by CO.DON makes us proud and confirms the considerable commitment undertaken by our company in this rapidly developing sector," said Alessia Zanelli, CEO of Comecer Group, in a company press release.
"We are delighted to have such an experienced partner as Comecer, with its many years of specialist expertise. Together we will perform this challenging task. CO.DON is entering a new dimension: once all the work is finished, the production site will be one of the world's largest and most modern plants for the industrial-scale production of human cells. It will enable us to ensure the supply of the highest quality cell therapy products to our customers in Germany and Europe going forward," added Ralf Jakobs, CEO of CO.DON AG, in the release.
Source: Comecer Group
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.